GLG News Analyses of the following article:
XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
Published at: www.pipelinereview.com
-
Epo in Myeloma: A good Idea. Will the Data Bear it Out?
March 23, 2009
Anemia is a big problem for many Myeloma patients. Recombinant Epo has been used to treat many different anemias, but its use has been severely restricted over the past few years due to reports of clotting complications and inadvertent tumor growth. Through an asset purchase agreement, XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) has agreed with Bio-GAL to acquire the "use patent" for Epo in the treatment of anemia in myeloma.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.